NEWS 
& MEDIA

MEDIA
CONTACT

Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.

If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com

For other Takeda news releases, please visit the Takeda.com Newsroom. 

GO TO TAKEDA NEWSROOM

NEWS
RELEASES

2/8/2019

European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe

READ MORE  
12/14/2018

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

READ MORE  
12/3/2018

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

READ MORE